Background Immunotherapy with T cells expressing chimeric antigen receptors (CARs)
specific for a tumor cell-surface molecule is effective for CD19+ B cell malignancies. There is …

Genetic engineering of T cells for adoptive transfer by introducing a tumor-targeting chimeric
antigen receptor (CAR) is a new approach to cancer immunotherapy. A challenge for the …

Purpose: The adoptive transfer of T cells modified to express a chimeric antigen receptor
(CAR) comprised of an extracellular single-chain antibody (scFV) fragment specific for a …

Adoptive therapy with T cells modified to express chimeric antigen receptors (CARs) holds
promise for treating epithelial cancers if target molecules can be identified and strategies …

Chimeric antigen receptor T cells (CAR T) have demonstrated robust clinical efficacy in B
cell and plasma cell malignancies. In contrast to success in these hematological …

Adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells is an
effective treatment for hematological malignancies that are refractory to conventional …

Background Immunotherapy with chimeric antigen receptor (CAR) T cells and bispecific T-
cell engagers (BiTEs) has shown impressive efficacy against CD19+ malignancies, but …

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has been shown to induce high
complete response rates in the majority of B-cell lymphoma patients. However, over 50% of …

Monoclonal antibodies and T cells modified to express chimeric antigen receptors specific
for B-cell lineage surface molecules such as CD20 exert antitumor activity in B-cell …

Abstract Background: Chimeric Antigen Receptor (CAR) T cell therapy is arguably one of the
most significant breakthroughs in cancer treatment. There are currently five FDA-approved …